CLL patients often have suboptimal COVID-19 vaccine responses and worse outcomes. GEO-CM04S1, a new type of vaccine, results in stronger T cell immunity.
People with CLL deserve accurate diagnosis, holistic care, and a voice in decision-making. This charter reflects input from patients, advocates, and experts.
People with CLL benefit from exercise, likely improving quality of life, yet they are rarely “prescribed” it and are less active than their peers.
Access important medications in the CLL Society Clinician Medicine Cabinet. Download key resources and order a Welcome Kit.
Discover CLL Society Clinician Resource Library CME offerings to improve care approaches for CLL and SLL patients.
Clinician Resource Library: Informational Handouts Click below on each of the topical handouts to view and print copies on demand. You may also order a free Welcome Kit which includes a
MRD-guided treatment with ibrutinib plus venetoclax significantly improved quality of life for patients with relapsed / refractory CLL.
NX-5948 is a novel type of drug, classified as a BTK degrader, and it has shown promising early clinical data.
CLL Society awarded Dr. Nancy Musoke a research grant for his project on Curcumin, Exercise and Placebo Effects on CLL / SLL Progression and Immune Function.
